Tubeless anesthesia to prevent lung complications during early-stage lung cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial compares tubeless anesthesia, which preserves spontaneous breathing without tracheal intubation, to traditional tracheal intubation in patients undergoing single-port thoracoscopic resection for early-stage lung cancer. Eligible adults (ECOG 0–1) with good cardiac and pulmonary function and peripheral lung nodules will be enrolled, while patients with obesity, difficult airways, heavy secretions, severe hypoxia/hypercapnia, or expected extensive pleural adhesions are excluded. Primary outcomes include contralateral lung complications, perioperative hemodynamics, complication rates, and recovery speed, with additional monitoring for safety and need to convert to intubation. The study collects intraoperative and postoperative data to compare feasibility, safety, and clinical recovery between the two anesthesia approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years and ≤70 years;
2. ECOG performance status score 0-1;
3. Good cardiac and pulmonary function;
4. Single or multiple peripheral lung nodules planned for single-port thoracoscopic surgery, with or without mediastinal lymph node dissection or sampling;
5. Able to comply with the study visit schedule and other protocol requirements;
6. Signed informed consent and voluntary participation in the study.

Exclusion Criteria:

1. Obese patients (BMI \>30);
2. Patients with difficult intubation or expected complex airway management;
3. COPD patients with copious airway secretions;
4. Patients with neurological dysfunction or who cannot cooperate while awake;
5. Patients expected to have extensive pleural adhesions or with previous lung resection;
6. Elderly and frail patients with severe hypoxia (PaO2 \<60 mmHg) or hypercapnia (PaCO2 \>50/55 mmHg);
7. Previous induction chemotherapy or chemoradiotherapy;
8. Intraoperative need to isolate the lung to prevent spillage and contamination of the contralateral lung;
9. Patients expected to have large surgical wounds and lengthy procedures, clinically assessed as unsuitable;
10. Patients whose cardiac and pulmonary function, or overall health, cannot withstand the procedure.

Where it's running

• Fujian Medical University Union Hospital
  Fuzhou, Fujian, China Recruiting

Study contacts

• Study coordinator: Shishi Huang
• Email: twolions1997@163.com
• Phone: +81 18120825212

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new radiotherapy approach for non-small cell lung cancer

  This study is testing a new way of giving radiotherapy to see if it helps people with advanced non-small cell lung cancer feel better by using breaks in treatment to make the tumors more sensitive to the radiation.

  Recruiting The Netherlands Cancer Institute · Amsterdam · NCT06528743

• Therapeutic cancer vaccine for patients with advanced lung cancer resistant to immunotherapy

  This study is testing a new cancer vaccine called OSE2101 to see if it can help people with advanced lung cancer who haven't responded to other immunotherapy treatments.

  Recruiting at 153 sites Phase 3 OSE Immunotherapeutics · Beverly Hills, California and 206 other locations · NCT06472245

• Using a brief swallowing test to detect vocal cord paralysis after major lung surgery

  This trial will test whether a quick swallowing test performed by a physiotherapist can find vocal cord paralysis in adults after major lung resection for lung cancer.

  Recruiting University Hospital, Rouen · Rouen · NCT05193240

• NXP900 plus osimertinib for advanced EGFR‑mutant non‑small cell lung cancer

  This trial will test whether adding NXP900 to osimertinib helps adults with advanced EGFR‑mutated non‑small cell lung cancer that has progressed on prior osimertinib.

  Recruiting at 5 sites Phase 1 Nuvectis Pharma, Inc. · Calverton, Maryland and 5 other locations · NCT07315113

• Comparing standard chemotherapy with immune-based combinations for relapsed stage III non-small-cell lung cancer after chemoradiotherapy and durvalumab

  This study tests whether adding durvalumab to second-line single-agent chemotherapy, or adding olaparib to durvalumab, helps people with stage III non-small-cell lung cancer who relapse after chemoradiotherapy and durvalumab live longer.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, RM · NCT05568212

• Detecting lung issues in rheumatoid arthritis patients

  This study is trying to create an easy-to-use online tool and app to help find lung problems in people with rheumatoid arthritis.

  Recruiting Medical University Innsbruck · Innsbruck, Austria · NCT06965322

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.